Jury investor panel member

Mathias Declercq | Senior Associate | DROIA Ventures

Mathias Declercq is a Senior Associate at Droia Ventures and joined the investment team in December 2021. His main focus is on the investment side, identifying, analyzing and preparing of investment opportunities and the monitoring of participations holding multiple multiple board observer roles across therapeutic areas and modalities.

Prior to joining Droia, Mathias obtained his PhD in Biomedical Sciences at the KU Leuven. His work in rare disease was collaboration between VIB-KU Leuven Center of Cancer Biology and UZ Leuven hospital. He also holds a MSc degree in Management from the same university.

About DROIA Ventures

Droia invests globally in young drug development companies that use novel science and innovative approaches to bring promising therapies to patients. We are specialists, investing exclusively in therapeutics for oncology and genetic disease. Our focus and our in-house team of drug development experts and biotech professionals allow us to accelerate our companies’ progress by actively supporting them from company creation through clinical proof of concept. We are hands-on investors and entrepreneurs, fully dedicated to making an impact and saving patient lives.